Summary
Pharmaceutical policy arises through an ongoing process of negotiation and interaction among the key players in the pharmaceutical market: consumers, industry, healthcare providers and government. There is constant discussion about the just distribution of reward between cost-containment goals and the goals of research and development in the pharmaceutical arena. All industrial countries are under pressure to control healthcare costs, but it is unclear how cost-containment policies will influence industrial policies for Pharmaceuticals. The pharmaceutical industry is an easy target for governmental cost-containment policies. The industry is driven by 3 issues: access to consumers, access to new technology and new competitive realities. The launch of a new, innovative product that represents a significant therapeutic breakthrough is becoming increasingly difficult, and a major challenge for politicians and governments will be to balance the need for cost-effective use of drugs and the need to create a favourable climate for innovation. Previously, there was generally little competition between pharmaceutical companies, but those companies will now have to undergo fundamental and comprehensive changes. Particularly, it will be important to have extremely well developed and integrated management systems focusing on both consumers and costs.
Similar content being viewed by others
References
James BG. The pharmaceutical industry in 2000: reinvesting the pharmaceutical company. London: The Economist Intelligence Unit, 1994
Abrahams P. Bitter medicines for producers [letter]. Financial Times 1994 Sep 30:2
Rettig RA. Medical innovation duels cost containment. Health Aff 1994 Summer: 7–28
Easton DA. System analysis of political life. Chicago: University Express, 1965
Øvretveit J. Purchasing for health. Philadelphia: Open University Press, 1995
Stigler G. The theory of economic regulation. Bell J Econ Manag Sci 1971; 2(1): 3–21
Drummond MF, Rutten F, Brenna A, et al. Economic evaluation of Pharmaceuticals: a European perspective. PharmacoEconomics 1993; 3: 173–86
Sosialdepartementet. Heisepolitikken mot år 2000: nasjonal heiseplan. Stortingsmelding nr. 41 (1987–88). Oslo: Sosial-departementet, 1988
Chain EB. Academic and industrial contributions to drug research. Nature 1963 Nov: 200–441
Siskind DA. Contributions of the pharmaceutical industry to improved health. In: Lindsay CM, editor. The pharmaceutical industry. New York: John Wiley & Sons, 1978
Hoffmeyer UK, McCarthy TR. Financing health care. Dordrecht: Kluwer Academic Publishers, 1994
Organisation for Economic Cooperation and Development (OECD). The reform of health care: a comparative analysis of seven countries. Paris: OECD, 1992
Abel-Smith B. Health reform: old wine in new bottles. Euro-health 1995; 1(1): 7–9
Maynard A. Whither OTC medicines? Swiss Pharma 1994; 5-S: 15–7
Anderson GM, Spitzer WO, Weinstein MC, et al. Benefits, risks and costs of prescription drugs: a scientific basis for evaluating policy options. Clin Pharmacol Ther 1990; 48: 111–9
Grund J, Husbyn H. The role of pharmacoeconomics in health policy and management in Norway. PharmacoEconomics 1995; 7(6): 475–83
Jönsson B. Economic evaluation of medicines: why and how? Nordiska Lakemedelsnamden 1995; 38: 11–9
Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Government Publishing Service, 1995
Porter ME. Competitive strategy. New York: Free Press, 1980
Commission of the European Communities. On the outlines of an industrial policy for the pharmaceutical sector in the European Community. COM (93) 718 final. Brussels: 02.03, 1994
Gelijns A, Rosenberg N. The dynamics of technological change in medicine. Health Aff 1994 Sum: 28–46
Hafslund Nycorned. Årsmelding 1994 [annual report]. Oslo: Hafslund Nycomed, 1995
Amdam RP, Sogner K. Rik på kontraster. Oslo: Ad Notam Gyldendal, 1994
Sogner K. Nations, clusters and culture: Nycomed and world leadership in the field of X-ray contrast media. Scand Econ Hist Rev 1993; 3: 209–20
Maynard A. The regulation of the pharmaceutical industry. In: Drummond MF, Maynard A, editors. Purchasing and providing cost-effective health care. London: Churchill Livingstone, 1993
Bloom D. In need of care [letter]. Economist 1995 Aug 12; 7927:4–5
Atkinson SH. University-affiliated venture capital funds. Health Aff 1994 Summer: 159–76
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grund, J. The Societal Value of Pharmaceuticals. Pharmacoeconomics 10, 14–22 (1996). https://doi.org/10.2165/00019053-199610010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199610010-00003